Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vancomycin
Drug ID BADD_D02332
Description Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make _Clostridium difficile_ associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].
Indications and Usage A variety of dosage forms (for example, oral, injections, etc.) exist for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci [FDA Label]. Additionally, a unique FDA approved oral liquid treatment is also available and indicated for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains [L1196].
Marketing Status approved
ATC Code A07AA09; J01XA01; S01AA28
DrugBank ID DB00512
KEGG ID D00212
MeSH ID D014640
PubChem ID 14969
TTD Drug ID D0B1IV
NDC Product Code 70594-056; 65628-200; 65628-201; 70594-058; 70594-041; 70594-043; 45932-0050; 70594-040; 70594-044; 70594-042; 70594-057
UNII 6Q205EH1VU
Synonyms Vancomycin | Vancomycin Hydrochloride | Hydrochloride, Vancomycin | Vancomycin Sulfate | Sulfate, Vancomycin | Vancomycin-ratiopharm | Vancomycin Hexal | Vancomycine Dakota | AB-Vancomycin | Vanco Azupharma | Diatracin | VANCO-cell | Vanco-saar | Vancocin | Vancocin HCl | Vancomycin Lilly | Vancocine | Vancomicina Abbott | Vancomicina Chiesi | Vancomicina Combino Phar | Vancomicina Norman | Vancomycin Phosphate (1:2) | Vancomycin Phosphate (1:2), Decahydrate
Chemical Information
Molecular Formula C66H75Cl2N9O24
CAS Registry Number 1404-90-6
SMILES CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)N C7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O) O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acute respiratory distress syndrome24.03.02.034; 10.02.01.067; 22.01.03.001--
Agranulocytosis01.02.03.001--Not Available
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Asthenia08.01.01.001--Not Available
Asthenopia06.01.01.002--Not Available
Azotaemia20.01.01.001--Not Available
Back pain15.03.04.005--
Blister23.03.01.001; 12.01.06.002--Not Available
Blood creatinine increased13.13.01.004--
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Cardiogenic shock02.05.01.003; 24.06.02.006--Not Available
Chills15.05.03.016; 08.01.09.001--
Clostridium difficile colitis11.02.02.004; 07.19.01.004--Not Available
Colitis ulcerative10.02.01.004; 07.08.01.005--Not Available
Constipation07.02.02.001--
Crohn's disease10.02.01.005; 07.08.01.015--Not Available
Deafness04.02.01.001--Not Available
Deafness neurosensory17.04.07.001; 04.02.01.002--Not Available
Deafness permanent17.04.07.002; 04.02.01.003--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene